NR4A1 and breast cancer: Therefore, for men with stage I–III hormone receptor-positive BC undergoing surgical treatment, adjuvant tamoxifen for 5 years is the therapy of choice, and it can be individually extended to 10 years based on tolerance and the risk of recurrence (26, 31).